Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure-Reference-Cited by-同舟云学术

Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure

Published:2004-11 Issue:11 Volume:13 Page:1509-1516
ISSN:1354-3784
Container-title:Expert Opinion on Investigational Drugs
language:en
Short-container-title:Expert Opinion on Investigational Drugs

Author:

Freudenberger Ronald S,Schwarz Jr Richard P,Brown Joanne,Moore Alan,Mann Douglas,Givertz Michael M,Colucci Wilson S,Hare Joshua M

Publisher

Informa Healthcare

Subject

Pharmacology (medical),Pharmacology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1517/13543784.13.11.1509

Reference26 articles.

1. On the Mechanism of Inactivation of Xanthine Oxidase by Allopurinol and Other Pyrazolo[3,4-d]pyrimidines

2. The Purine Path to Chemotherapy

3. Uric Acid and Survival in Chronic Heart Failure

4. Uric Acid Predicts Clinical Outcomes in Heart Failure

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cardiac remodeling in chronic heart failure: pathophysiological implications;Pathophysiology, Risk Factors, and Management of Chronic Heart Failure;2024

2. The involvement of reactive oxygen species in causing chronic cardiovascular and neurodegenerative diseases and some cancers;Scripta Medica;2024

3. Consensus on patients with hyperuricemia and high cardiovascular risk treatment: 2022;Systemic Hypertension;2022-11-16

4. Future scope and challenges for congestive heart failure: moving toward development of pharmacotherapy;Canadian Journal of Physiology and Pharmacology;2022-09-01

5. Cancer Mortality in Trials of Heart Failure With Reduced Ejection Fraction: A Systematic Review and Meta‐Analysis;Journal of the American Heart Association;2020-09-15